Compare OCGN & ERII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OCGN | ERII |
|---|---|---|
| Founded | 2013 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Machinery/Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 419.8M | 437.1M |
| IPO Year | 2014 | 2008 |
| Metric | OCGN | ERII |
|---|---|---|
| Price | $1.29 | $8.49 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 3 |
| Target Price | $9.75 | ★ $17.07 |
| AVG Volume (30 Days) | ★ 5.7M | 638.8K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.58 | 5.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $134,987,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1,718.38 | $20.55 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.93 | $7.83 |
| 52 Week High | $2.73 | $18.31 |
| Indicator | OCGN | ERII |
|---|---|---|
| Relative Strength Index (RSI) | 40.03 | 42.46 |
| Support Level | $1.13 | $8.14 |
| Resistance Level | $1.58 | $9.10 |
| Average True Range (ATR) | 0.07 | 0.27 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 18.75 | 7.44 |
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
Energy Recovery Inc designs and manufactures energy-saving technologies. The firm uses its proprietary pressure exchanger technology to help customers in multiple industries improve their operations and lower their emissions. Using its proprietary technology, it offers energy recovery devices, including pressure exchangers, pumps, and turbochargers, mainly used for seawater desalination and wastewater treatment. Additionally, the company is involved in the development of emerging technologies, such as the PX G1300 used in industrial and commercial refrigeration applications. The firm's reportable operating segments are: Water, which generates maximum revenue, and Emerging Technologies. Geographically, it generates maximum revenue from the Middle East, and the rest from other markets.